Prevention of poststroke apathy using escitalopram or problem-solving therapy

Katsunaka Mikami, Ricardo E. Jorge, David J. Moser, Stephan Arndt, Mijin Jang, Ana Solodkin, Steven L. Small, Pasquale Fonzetti, Mark T. Hegel, Robert G. Robinson

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objective: Apathy occurs frequently following stroke and prior studies have demonstrated the negative effect of apathy on recovery from stroke. This study was a secondary analysis examining the efficacy of escitalopram, problem-solving therapy (PST), or placebo administered for 1 year to prevent the onset of apathy among patients with recent stroke. Methods: Patients within 3 months of an index stroke who did not meet DSM-IV diagnostic criteria for major or minor depression and who did not have a serious comorbid physical illness were enrolled. Patients were recruited from three sites: University of Iowa, University of Chicago, and Burke Rehabilitation Hospital. One hundred fifty-four patients without evidence of apathy at initial evaluation were included in the randomized controlled trial using escitalopram (10 mg patients ≤65 years; 5 mg patients >65 years) (N = 51) or placebo (N = 47) or non-blinded PST (12 total sessions) (N = 56) over 1 year. At 3, 6, 9, and 12 months, patients were assessed for diagnosis and severity of apathy using the Apathy Scale. Results: Using a Cox proportional hazards model of time to onset of apathy, participants given placebo were 3.47 times more likely to develop apathy than patients given escitalopram and 1.84 times more likely to develop apathy than patients given PST after controlling for age, sex, cognitive impairment, and diabetes mellitus status (adjusted hazard ratio: 3.47, 95% CI: 1.79e6.73 [escitalopram group]; adjusted hazard ratio: 1.84, 95% CI: 1.21-2.80 [PST group]). Conclusion: Escitalopram or PST was significantly more effective in preventing new onset of apathy following stroke compared with placebo.

Original languageEnglish (US)
Pages (from-to)855-862
Number of pages8
JournalAmerican Journal of Geriatric Psychiatry
Volume21
Issue number9
DOIs
StatePublished - Sep 2013
Externally publishedYes

Fingerprint

Apathy
Citalopram
Stroke
Placebos
Therapeutics
Group Psychotherapy
Proportional Hazards Models
Diagnostic and Statistical Manual of Mental Disorders
Diabetes Mellitus
Rehabilitation
Randomized Controlled Trials
Depression

Keywords

  • Apathy
  • Prevention
  • Stroke

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Mikami, K., Jorge, R. E., Moser, D. J., Arndt, S., Jang, M., Solodkin, A., ... Robinson, R. G. (2013). Prevention of poststroke apathy using escitalopram or problem-solving therapy. American Journal of Geriatric Psychiatry, 21(9), 855-862. https://doi.org/10.1016/j.jagp.2012.07.003

Prevention of poststroke apathy using escitalopram or problem-solving therapy. / Mikami, Katsunaka; Jorge, Ricardo E.; Moser, David J.; Arndt, Stephan; Jang, Mijin; Solodkin, Ana; Small, Steven L.; Fonzetti, Pasquale; Hegel, Mark T.; Robinson, Robert G.

In: American Journal of Geriatric Psychiatry, Vol. 21, No. 9, 09.2013, p. 855-862.

Research output: Contribution to journalArticle

Mikami, K, Jorge, RE, Moser, DJ, Arndt, S, Jang, M, Solodkin, A, Small, SL, Fonzetti, P, Hegel, MT & Robinson, RG 2013, 'Prevention of poststroke apathy using escitalopram or problem-solving therapy', American Journal of Geriatric Psychiatry, vol. 21, no. 9, pp. 855-862. https://doi.org/10.1016/j.jagp.2012.07.003
Mikami, Katsunaka ; Jorge, Ricardo E. ; Moser, David J. ; Arndt, Stephan ; Jang, Mijin ; Solodkin, Ana ; Small, Steven L. ; Fonzetti, Pasquale ; Hegel, Mark T. ; Robinson, Robert G. / Prevention of poststroke apathy using escitalopram or problem-solving therapy. In: American Journal of Geriatric Psychiatry. 2013 ; Vol. 21, No. 9. pp. 855-862.
@article{9eba1d1f39b943b18ec1b2772fd55719,
title = "Prevention of poststroke apathy using escitalopram or problem-solving therapy",
abstract = "Objective: Apathy occurs frequently following stroke and prior studies have demonstrated the negative effect of apathy on recovery from stroke. This study was a secondary analysis examining the efficacy of escitalopram, problem-solving therapy (PST), or placebo administered for 1 year to prevent the onset of apathy among patients with recent stroke. Methods: Patients within 3 months of an index stroke who did not meet DSM-IV diagnostic criteria for major or minor depression and who did not have a serious comorbid physical illness were enrolled. Patients were recruited from three sites: University of Iowa, University of Chicago, and Burke Rehabilitation Hospital. One hundred fifty-four patients without evidence of apathy at initial evaluation were included in the randomized controlled trial using escitalopram (10 mg patients ≤65 years; 5 mg patients >65 years) (N = 51) or placebo (N = 47) or non-blinded PST (12 total sessions) (N = 56) over 1 year. At 3, 6, 9, and 12 months, patients were assessed for diagnosis and severity of apathy using the Apathy Scale. Results: Using a Cox proportional hazards model of time to onset of apathy, participants given placebo were 3.47 times more likely to develop apathy than patients given escitalopram and 1.84 times more likely to develop apathy than patients given PST after controlling for age, sex, cognitive impairment, and diabetes mellitus status (adjusted hazard ratio: 3.47, 95{\%} CI: 1.79e6.73 [escitalopram group]; adjusted hazard ratio: 1.84, 95{\%} CI: 1.21-2.80 [PST group]). Conclusion: Escitalopram or PST was significantly more effective in preventing new onset of apathy following stroke compared with placebo.",
keywords = "Apathy, Prevention, Stroke",
author = "Katsunaka Mikami and Jorge, {Ricardo E.} and Moser, {David J.} and Stephan Arndt and Mijin Jang and Ana Solodkin and Small, {Steven L.} and Pasquale Fonzetti and Hegel, {Mark T.} and Robinson, {Robert G.}",
year = "2013",
month = "9",
doi = "10.1016/j.jagp.2012.07.003",
language = "English (US)",
volume = "21",
pages = "855--862",
journal = "American Journal of Geriatric Psychiatry",
issn = "1064-7481",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Prevention of poststroke apathy using escitalopram or problem-solving therapy

AU - Mikami, Katsunaka

AU - Jorge, Ricardo E.

AU - Moser, David J.

AU - Arndt, Stephan

AU - Jang, Mijin

AU - Solodkin, Ana

AU - Small, Steven L.

AU - Fonzetti, Pasquale

AU - Hegel, Mark T.

AU - Robinson, Robert G.

PY - 2013/9

Y1 - 2013/9

N2 - Objective: Apathy occurs frequently following stroke and prior studies have demonstrated the negative effect of apathy on recovery from stroke. This study was a secondary analysis examining the efficacy of escitalopram, problem-solving therapy (PST), or placebo administered for 1 year to prevent the onset of apathy among patients with recent stroke. Methods: Patients within 3 months of an index stroke who did not meet DSM-IV diagnostic criteria for major or minor depression and who did not have a serious comorbid physical illness were enrolled. Patients were recruited from three sites: University of Iowa, University of Chicago, and Burke Rehabilitation Hospital. One hundred fifty-four patients without evidence of apathy at initial evaluation were included in the randomized controlled trial using escitalopram (10 mg patients ≤65 years; 5 mg patients >65 years) (N = 51) or placebo (N = 47) or non-blinded PST (12 total sessions) (N = 56) over 1 year. At 3, 6, 9, and 12 months, patients were assessed for diagnosis and severity of apathy using the Apathy Scale. Results: Using a Cox proportional hazards model of time to onset of apathy, participants given placebo were 3.47 times more likely to develop apathy than patients given escitalopram and 1.84 times more likely to develop apathy than patients given PST after controlling for age, sex, cognitive impairment, and diabetes mellitus status (adjusted hazard ratio: 3.47, 95% CI: 1.79e6.73 [escitalopram group]; adjusted hazard ratio: 1.84, 95% CI: 1.21-2.80 [PST group]). Conclusion: Escitalopram or PST was significantly more effective in preventing new onset of apathy following stroke compared with placebo.

AB - Objective: Apathy occurs frequently following stroke and prior studies have demonstrated the negative effect of apathy on recovery from stroke. This study was a secondary analysis examining the efficacy of escitalopram, problem-solving therapy (PST), or placebo administered for 1 year to prevent the onset of apathy among patients with recent stroke. Methods: Patients within 3 months of an index stroke who did not meet DSM-IV diagnostic criteria for major or minor depression and who did not have a serious comorbid physical illness were enrolled. Patients were recruited from three sites: University of Iowa, University of Chicago, and Burke Rehabilitation Hospital. One hundred fifty-four patients without evidence of apathy at initial evaluation were included in the randomized controlled trial using escitalopram (10 mg patients ≤65 years; 5 mg patients >65 years) (N = 51) or placebo (N = 47) or non-blinded PST (12 total sessions) (N = 56) over 1 year. At 3, 6, 9, and 12 months, patients were assessed for diagnosis and severity of apathy using the Apathy Scale. Results: Using a Cox proportional hazards model of time to onset of apathy, participants given placebo were 3.47 times more likely to develop apathy than patients given escitalopram and 1.84 times more likely to develop apathy than patients given PST after controlling for age, sex, cognitive impairment, and diabetes mellitus status (adjusted hazard ratio: 3.47, 95% CI: 1.79e6.73 [escitalopram group]; adjusted hazard ratio: 1.84, 95% CI: 1.21-2.80 [PST group]). Conclusion: Escitalopram or PST was significantly more effective in preventing new onset of apathy following stroke compared with placebo.

KW - Apathy

KW - Prevention

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=84884551108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884551108&partnerID=8YFLogxK

U2 - 10.1016/j.jagp.2012.07.003

DO - 10.1016/j.jagp.2012.07.003

M3 - Article

C2 - 23930743

AN - SCOPUS:84884551108

VL - 21

SP - 855

EP - 862

JO - American Journal of Geriatric Psychiatry

JF - American Journal of Geriatric Psychiatry

SN - 1064-7481

IS - 9

ER -